Craft

Lineage Cell Therapeutics

Stock Price

$0.9

2024-10-29

Market Capitalization

$166.5 M

2024-10-29

Revenue

$14.6 M

FY, 2025

Lineage Cell Therapeutics Summary

Company Summary

Overview
Lineage Cell Therapeutics (formerly known as BioTime) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. It develops a cell-based therapy platform that manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials.
Type
Public
Status
Active
Founded
1990
HQ
Carlsbad, CA, US | view all locations
Website
https://lineagecell.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Brian Culley

    Brian Culley, Chief Executive Officer, Director

  • Neal C. Bradsher, Director

    • Derek Kelaita

      Derek Kelaita, Vice President, Business Development

    • George A. Samuel III

      George A. Samuel III, General Counsel & Corporate Secretary

    Operating MetricsView all

    Patents Issued

    850

    FY, 2016

    LocationsView all

    3 locations detected

    • Carlsbad, CA HQ

      United States

      2173 Salk Ave #200

    • Alameda, CA

      United States

      1010 Atlantic Ave #102

    • Jerusalem, Jerusalem District

      Israel

    Lineage Cell Therapeutics Financials

    Summary Financials

    Revenue (Q1, 2026)
    $1.7M
    Net income (Q1, 2026)
    ($4.8M)
    Cash (Q1, 2026)
    $35.9M
    EBIT (Q1, 2026)
    ($7.6M)
    Enterprise value
    $132.9M

    Footer menu